Achieving UNAIDS 90: 90:90 requires effective prevention programmes that focus on demographic and geographic hotspots.

Achieving UNAIDS 90: 90:90 requires effective prevention programmes that focus on demographic and geographic hotspots.

Its barely two years to the UNAIDS 2020 target of 90:90:90 – identifying 90% of people living with HIV; placing 90% of those living with HIV on treatment; and ensuring viral suppression of 90% of those persons on treatment. With over three decades of investment and progress in the fight against HIV, the international health community begins to envisage the possibility of an end to the pandemic. This achievement of this aspiration goal requires investment in strategies that enables programmes reach people who are at the greatest risk of HIV acquisition and transmission. Persons at great risk of HIV acquisition need fast tracked access to multiple prevention modalities to meet their varied needs. Access to HIV prevention tools need to be fast tracked to end the AIDS by 2030. Communities need to make all known effective HIV prevention modalities –  Treatment as Prevention, PrEP, PEP, Condom, behavior change – available especially to persons resident  in demographic and geographic hotspots that are key drivers of HIV transmission and acquisition.
The number of people living with HIV and the rate of new HIV infection within each geographical location varies at different  times.  It is also important to identify those persons with key demographic characteristicsthat  are drivers of HIV epidemics. It is important to identify and reach people with these demographics  in those areas where people at high risk for HIV infection, or people living with HIV are geographically concentrated in every country, region and district that drives the epidemic, and make HIV prevention tools readily available to people who need it most. This will help to to abruptly control the epidemic.
STI treatment site user fee; a major challenge to PrEP uptake and adherence for PrEP users. – Orobosa Enadeghe

STI treatment site user fee; a major challenge to PrEP uptake and adherence for PrEP users. – Orobosa Enadeghe

Oral Pre-Exposure Prophylaxis (PrEP) is a powerful prevention tool that can reduce the risk of HIV infection by 92% or more when taken as directed. PrEP is increasingly being adopted around the world even in low and middle income countries. PrEP users are however required to pay out of pocket for routine tests eg STI testing and treatment service needed during PrEP uptake. The people who are most in need of PrEP often may not have the resources. This treatment site user fees for PrEP access remains a great challenge for people who use PrEP especially in low income countries. This could consequently affect PrEP users’ adherence and retention in care if they are unable to pay for the routine test services. There is therefore need to explore and provide ways to increase PrEP users access to low cost diagnostics or free quality STI services over the long run.
By Orobosa Enadeghe
Is an HIV vaccine necessary for ending AIDS? – Orobosa Enadeghe

Is an HIV vaccine necessary for ending AIDS? – Orobosa Enadeghe

Yes. It is difficult to envisage control of HIV epidemic without an effective vaccine. Though an effective HIV vaccine has not been discovered yet, researchers are invested in discovering one despite the huge resources required for this process. A HIV vaccine could be developed for preventive and therapeutic purposes. A preventive vaccine would help make HIV-negative people less likely to contract HIV infection. The therapeutic vaccine will reduce the risk of people living with HIV progressing to AIDS as it will make their immune systems stronger and better able to control the virus. Vaccines have been effective in the control of diseases including smallpox and polio. With a preventive  HIV vaccine the long term effect is protection of the community also with reduced risk of contracting new infections known as herd immunity. A HIV vaccine is therefore necessary to provide long lasting solution against HIV infection and reducing the risk for AIDS. When discovered, it will not preclude the use of other biomedical HIV prevention tools to help end the HIV pandemic.
By Orobosa Enadeghe
Advocates need to build the capacity of the broader community to support PrEP – Orobosa Enadeghe

Advocates need to build the capacity of the broader community to support PrEP – Orobosa Enadeghe

Pre-Exposure Prophylaxis (PrEP) is antiretroviral drugs taken daily by HIV negative people who are at substantial risk of HIV infection, to reduce their chances of becoming infected. It is an exciting evidence based method for HIV prevention that is increasingly being adopted around the world. It is over 90% effective for HIV prevention when taken consistently. People who need PrEP also need PrEP literacy to enhance its uptake. Persons who are in need of PrEP include persons with multiple sexual partners and who engage in transactional sex who are HIV negative, persons who do not use condoms correctly and consistently and persons in HIV serodiscordant relationships.  PrEP uptake and use may however be challenging for persons who live in communities that discriminate, stigmatise and reject PrEP users. Critical community stakehodlers that can impact on PrEP access include policy makers, journalists, medical practitioners, religious leaders. Thus, there is the need to educate community members about the benefits of PrEP and to sustain advocacy that promote its uptake and adherence to its use.
By Orobosa Enadeghe 

Rappourteur’s report – Poster Discussion (PD04): PrEP: Doing It Right at Delivery

Poster Discussion (PD04): PrEP: Doing It Right at Delivery

Hyman Scott from the San Francisco Department of Public Health presented on PrEP use and interest among MSM (n=1,088) recruited on a gay social networking app from six cities across the United States. PrEP use was high, with 44% reporting current PrEP use. An encouraging 63% of non-users expressed interest in using PrEP, with higher interest among younger MSM and those reporting more condomless anal intercourse. Alex Carballo-Diéguez from Columbia University and NY State Psychiatric University reported on the high acceptability and likelihood of use of a rectal microbicide douche among MSM and transgender women who engage in anal intercourse in the United States. A national internet-based survey (n=4,751) found that the majority of this population currently used a douche before anal intercourse. Almost all (98%) of those who reported a recent history of rectal douching and 94% of those who did not douche stated that they would likely use a rectal microbicide douche to prevent HIV, and 95% of those who reported only insertive anal intercourse stated that they would support a partner’s use of an HIV-preventive douche. Additionally, qualitative interviews conducted with participants (n=12) after completion of a phase 1 rectal microbicide douche trial reported high acceptability and high likelihood of use. A key quote from a participant that highlights the behavioral congruence of this strategy is as follows “I douche anyway, so it’s part of our routine…It’s like washing my hands before I eat”

Jayne Osindo from the African Population and Health Research Center reported on community and implementer perceptions of the girl-focused DREAMS programme in two Nairobi slums. While adolescent boys and young men also benefited from the programme, there were concerns from both the boys themselves as well as community members that they were missing out on social protection interventions and HIV prevention information. Fernandos Ongolly from the Kenya Medical Research Institute reported on the broadly positive experiences of serodiscordant couples accessing PrEP in public HIV clinics in Kenya, with particular benefits of shared decision-making regarding PrEP initiation.